enow.com Web Search

  1. Ad

    related to: sglt2i approved for heart failure mayo clinic
    • Efficacy

      View Efficacy & Data Information.

      First Line Treatment Option.

    • Clinical Data

      Clinical Trial Data For HCPs.

      Learn More About Heart Failure.

    • Things You Should Know

      View Important Safety Information.

      Heart Failure Facts & Information.

    • Safety Data

      Safety & Warning Info For HCPs.

      Review Clinical Trail Data On HF.

Search results

  1. Results from the WOW.Com Content Network
  2. SGLT2 inhibitor - Wikipedia

    en.wikipedia.org/wiki/SGLT2_inhibitor

    Sotagliflozin (Inpefa) is a dual SGLT1/SGLT2 inhibitor approved by the US Food and Drug Administration (FDA) in May 2023, to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors ...

  3. Empagliflozin - Wikipedia

    en.wikipedia.org/wiki/Empagliflozin

    Empagliflozin lowers risk of hospitalization and death in people with reduced heart function, when added to standard heart failure treatment with or without type 2 diabetes. [ 29 ] [ 30 ] [ 31 ] It is indicated in adults with type 2 diabetes and established cardiovascular disease to reduce the risk of cardiovascular death; and as an adjunct to ...

  4. GLP-1 receptor agonist - Wikipedia

    en.wikipedia.org/wiki/GLP-1_receptor_agonist

    GLP-1 agonists were developed initially for type 2 diabetes. [5] The 2022 American Diabetes Association (ADA) standards of medical care in diabetes include GLP-1 agonist or SGLT2 inhibitor as a first line pharmacological therapy for type 2 diabetes in patients who have or are at high risk for atherosclerotic cardiovascular disease or heart failure.

  5. Pairing Drugs Like Ozempic with SGLT2 Meds May Help ... - AOL

    www.aol.com/pairing-drugs-ozempic-sglt2-meds...

    Combining GLP-1 drugs like Ozempic with SGLT2 diabetes medications may help reduce the risk of heart attacks, stroke, and kidney disease, new research suggests.

  6. Dapagliflozin - Wikipedia

    en.wikipedia.org/wiki/Dapagliflozin

    Dapagliflozin is used along with diet, exercise, and usually with other glucose-lowering medications, to improve glycaemic control in adults with type 2 diabetes. . Dapagliflozin, in addition to other SGLT2-inhibitors, was shown to reduce the rate of decline in kidney function and kidney failure in non-diabetic and type 2 diabetic adults when added to the existing treatment

  7. Canagliflozin - Wikipedia

    en.wikipedia.org/wiki/Canagliflozin

    Canagliflozin is indicated to be used with diet and exercise to lower blood sugar in adults with type 2 diabetes; to reduce the risk of major heart-related events such as heart attack, stroke, or death in people with type 2 diabetes who have known heart disease; and to reduce the risk of end-stage kidney disease, worsening of kidney function, heart-related death, and being hospitalized for ...

  8. ‘I’m a Cardiologist—Here’s What I Want Everyone To Know about ...

    www.aol.com/m-cardiologist-want-everyone-know...

    Related: 20 Registered Dietitian-Approved Heart-Healthy Snacks That Taste Great, Too. Sources. Dr. Yaz Debull, MD, cardiologist who uses social media to educate people about cardiovascular health.

  9. Wegovy Maker Novo Nordisk's Oral Diabetes Pill Cuts Heart ...

    www.aol.com/wegovy-maker-novo-nordisks-oral...

    On Monday, Novo Nordisk A/S (NYSE:NVO) released the headline results from the SOUL Phase 3 cardiovascular outcomes trial. Last year, Novo Nordisk’s subcutaneous once-weekly (injectable ...

  1. Ad

    related to: sglt2i approved for heart failure mayo clinic